Navigation Links
New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event
Date:5/24/2012

SAN ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An advisory board of industry leaders at the 2012 Texas Life Science Venture Forum in Houston, Texas namedTransCU O2®, a cutting-edge therapy for chronic wounds, one of ten Most Promising Life Science Technologies.  Over 60 companies were invited to present their research and innovations to hundreds of early-stage investors, venture capitalists, and industry leaders.

This award represents another important achievement for Electrochemical Oxygen Concepts (EO2), the maker of the TransCU O2®.  The company has also recently received recognition by the Department of Veterans Affairs.  EO2 CEO Michael Wells says he and his team are honored by the accolades.

"Patients suffering from chronic wounds and their physicians have long been in need of a better therapy to treat their condition," said Wells. "This award from the Texas Life Science Venture Forum further confirms that TransCU O2® is a ground breaking therapy with the ability to improve the health and lives of patients who suffer with difficult-to heal wounds."

The TransCU O2® is a simple-to-use and easy-to-administer therapy that provides a continuous supply of low-dose pure oxygen to treat a variety of wound types such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.  Oxygen-based therapies have been proven effective in treating chronic wounds but current therapeutic approaches do not allow for 24-hour a day wound treatment.  The TransCU O2® device is lightweight and fully portable.  Its advanced technology allows for the constant monitoring and automatic flow adjustments necessary for the delivery of optimum therapeutic oxygen flow to the wound site.

The Texas Life Science Venture Forum is a joint effort between the Rice Alliance of Technology and Entrepreneurship, BioHouston, and the Texas Healthcare and BioScience Institute and part of the three-day Texas Life Science Conference.  The conference is the most comprehensive showcase of cutting-edge research and innovative entrepreneurs in the state.  Hundreds of investors, entrepreneurs, successful business people and industry leaders attended to learn about, evaluate and network with the presenting companies.

About Electrochemical Oxygen Concepts (EO2™ Concepts):
EO2™ Concepts is a privately held advanced wound care technology company and the developer of an innovative FDA cleared Class III medical device that provides therapy to difficult-to-heal wounds.  The TransCu O2® is an electrochemical low-dose tissue oxygenation and wound monitoring system designed for use with advanced wound dressings as an adjunctive therapy to treat oxygen compromised wounds.  TransCU O2® is a registered trade mark of Electrochemical Oxygen Concepts.  For more information, please visit www.eo2concepts.com.  

Media Contact: Megan Augustine Megan Augustine, 210-296-9520, mg.augustine@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Electrochemical Oxygen Concepts
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
3. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
4. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
5. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
6. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
9. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
10. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
11. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern ... DDS, are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of ... the Gateway Convention Center in Collinsville. , They expect to treat ...
Breaking Medicine News(10 mins):